Citadel Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.8M | Sell |
124,794
-4,972,002
| -98% | -$71.3M | ﹤0.01% | 6294 |
|
|
2025
Q4 | $72.6M | Sell |
5,096,796
-3,153,344
| -38% | -$31M | 0.01% | 1101 |
|
|
2025
Q3 | $65M | Buy |
8,250,140
+2,275,497
| +38% | +$16.2M | 0.01% | 1149 |
|
|
2025
Q2 | $34.2M | Sell |
5,974,643
-1,864,900
| -24% | -$12M | 0.01% | 1554 |
|
|
2025
Q1 | $64M | Sell |
7,839,543
-400,406
| -5% | -$3.71M | 0.01% | 965 |
|
|
2024
Q4 | $77.6M | Buy |
8,239,949
+4,609,786
| +127% | +$47.9M | 0.01% | 908 |
|
|
2024
Q3 | $38.8M | Buy |
3,630,163
+613,267
| +20% | +$6.68M | 0.01% | 1454 |
|
|
2024
Q2 | $29.9M | Buy |
3,016,896
+1,665,714
| +123% | +$17.1M | 0.01% | 1605 |
|
|
2024
Q1 | $15.9M | Buy |
1,351,182
+1,308,411
| +3,059% | +$16.7M | ﹤0.01% | 2330 |
|
|
2023
Q4 | $607K | Buy |
42,771
+6,415
| +18% | +$72.8K | ﹤0.01% | 7675 |
|
|
2023
Q3 | $442K | Buy |
36,356
+31,557
| +658% | +$407K | ﹤0.01% | 8327 |
|
|
2023
Q2 | $60.3K | Sell |
4,799
-499,177
| -99% | -$5.92M | ﹤0.01% | 11585 |
|
|
2023
Q1 | $5.59M | Buy |
503,976
+376,877
| +297% | +$4.65M | ﹤0.01% | 3621 |
|
|
2022
Q4 | $1.55M | Sell |
127,099
-1,701,360
| -93% | -$19.2M | ﹤0.01% | 5972 |
|
|
2022
Q3 | $19.1M | Sell |
1,828,459
-1,899,081
| -51% | -$21.2M | ﹤0.01% | 1921 |
|
|
2022
Q2 | $40M | Buy |
3,727,540
+2,185,467
| +142% | +$18M | 0.01% | 1195 |
|
|
2022
Q1 | $14.6M | Sell |
1,542,073
-27,629
| -2% | -$259K | ﹤0.01% | 2405 |
|
|
2021
Q4 | $18.1M | Sell |
1,569,702
-1,304,692
| -45% | -$14.5M | ﹤0.01% | 2144 |
|
|
2021
Q3 | $27.4M | Buy |
2,874,394
+1,501,395
| +109% | +$15.4M | 0.01% | 1653 |
|
|
2021
Q2 | $13.2M | Buy |
1,372,999
+882,896
| +180% | +$8.62M | ﹤0.01% | 2650 |
|
|
2021
Q1 | $4.84M | Buy |
490,103
+123,920
| +34% | +$1.92M | ﹤0.01% | 4324 |
|
|
2020
Q4 | $8.46M | Sell |
366,183
-536,548
| -59% | -$11M | ﹤0.01% | 2868 |
|
|
2020
Q3 | $12.7M | Sell |
902,731
-893,270
| -50% | -$13M | ﹤0.01% | 2004 |
|
|
2020
Q2 | $27.1M | Sell |
1,796,001
-279,427
| -13% | -$3.4M | 0.01% | 1237 |
|
|
2020
Q1 | $19.2M | Sell |
2,075,428
-1,797,071
| -46% | -$17.1M | 0.01% | 1269 |
|
|
2019
Q4 | $37.7M | Sell |
3,872,499
-914,428
| -19% | -$8.37M | 0.02% | 969 |
|
|
2019
Q3 | $38.4M | Sell |
4,786,927
-8,582
| -0.2% | -$93.1K | 0.02% | 945 |
|
|
2019
Q2 | $59.8M | Sell |
4,795,509
-1,638,905
| -25% | -$20.8M | 0.03% | 628 |
|
|
2019
Q1 | $87.5M | Buy |
6,434,414
+5,562,878
| +638% | +$68M | 0.04% | 416 |
|
|
2018
Q4 | $8.35M | Buy |
871,536
+722,864
| +486% | +$7.95M | ﹤0.01% | 2119 |
|
|
2018
Q3 | $1.8M | Buy |
+148,672
| New | +$2.08M | ﹤0.01% | 4585 |
|
|
2018
Q2 | – | Sell |
-394,169
| Closed | -$5.96M | – | 8960 |
|
|
2018
Q1 | $5.93M | Sell |
394,169
-3,276,499
| -89% | -$49.9M | ﹤0.01% | 2278 |
|
|
2017
Q4 | $52.8M | Buy |
3,670,668
+1,794,110
| +96% | +$24.6M | 0.03% | 587 |
|
|
2017
Q3 | $28.3M | Sell |
1,876,558
-934,830
| -33% | -$12.4M | 0.02% | 864 |
|
|
2017
Q2 | $28.3M | Buy |
2,811,388
+1,418,331
| +102% | +$11.4M | 0.02% | 793 |
|
|
2017
Q1 | $9.93M | Buy |
1,393,057
+1,086,006
| +354% | +$6.87M | 0.01% | 1444 |
|
|
2016
Q4 | $1.53M | Sell |
307,051
-71,590
| -19% | -$495K | ﹤0.01% | 3285 |
|
|
2016
Q3 | $2.8M | Sell |
378,641
-202,293
| -35% | -$1.37M | ﹤0.01% | 2569 |
|
|
2016
Q2 | $3.17M | Buy |
+580,934
| New | +$4.06M | ﹤0.01% | 2256 |
|
|
2016
Q1 | – | Sell |
-17,343
| Closed | -$123K | – | 7146 |
|
|
2015
Q4 | $168K | Sell |
17,343
-4,259,940
| -100% | -$38.4M | ﹤0.01% | 6027 |
|
|
2015
Q3 | $59.8M | Buy |
4,277,283
+312,011
| +8% | +$4.89M | 0.06% | 357 |
|
|
2015
Q2 | $56.1M | Buy |
3,965,272
+45,195
| +1% | +$543K | 0.05% | 454 |
|
|
2015
Q1 | $42.6M | Buy |
3,920,077
+1,570,562
| +67% | +$13.8M | 0.04% | 552 |
|
|
2014
Q4 | $19.5M | Buy |
2,349,515
+2,318,393
| +7,449% | +$15.9M | 0.02% | 962 |
|
|
2014
Q3 | $185K | Buy |
+31,122
| New | +$163K | ﹤0.01% | 5799 |
|
|
2014
Q1 | – | Sell |
-11,281
| Closed | -$27K | – | 7889 |
|
|
2013
Q4 | $27K | Buy |
11,281
+3,845
| +52% | +$8.44K | ﹤0.01% | 6311 |
|
|
2013
Q3 | $17K | Sell |
7,436
-12,650
| -63% | -$31.7K | ﹤0.01% | 6302 |
|
|
2013
Q2 | $47K | Buy |
+20,086
| New | +$61.7K | ﹤0.01% | 5701 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Citadel Advisors's FOLD Position: Q1 2026 in Review
Citadel Advisors reduced its Amicus Therapeutics (FOLD) stake by 98% in Q1 2026, selling an estimated $71.3M and leaving 124,794 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #6294.
Citadel Advisors first reported a position in FOLD in Q2 2013 and has held it in 48 quarters since. The position peaked at $87.5M in Q1 2019. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Citadel Advisors held 124,794 shares of Amicus Therapeutics worth $1.8M as of Q1 2026.
- Citadel Advisors sold 4,972,002 Amicus Therapeutics shares in Q1 2026, an estimated $71.3M.
- Amicus Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6294 holding.
- Citadel Advisors first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 48 quarters since.
- Citadel Advisors's Amicus Therapeutics position peaked at $87.5M in Q1 2019.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.